肿瘤新抗原mRNA疫苗在加速审批的背景下，肿瘤突变抗原的研究价值越来越大，为此，我们通过文献挖掘，为读者整理了各种肿瘤的已验证肿瘤突变抗原清单，我们将陆续发布。
以下是目前公布的胃癌肿瘤抗原肽清单，该清单均支持定制生产 (定制咨询请扫描本页右侧联系人二维码)。可定制生产：
- 检测或分选抗原特异性T细胞的流式试剂、磁珠分选试剂
- 构建抗原肽和MHC复合物，用于合成人工呈递物，从而刺激T细胞增殖
胃癌抗原蛋白的抗原肽数量分布
| Antigen Name | Description | Allele Name | paper |
|---|---|---|---|
| Protein E7 | YMLDLQPETT | HLA-A*02:01 | Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996 |
| Squamous cell carcinoma antigen recognized by T-cells 3 | VYDYNCHVDL | HLA-A*24:02 | Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004 |
| Squamous cell carcinoma antigen recognized by T-cells 3 | AYIDFEMKI | HLA-A*24:02 | Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004 |
| Tyrosine-protein kinase Lck | DYLRSVLEDF | HLA-A*24:02 | Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004 |
| Peptidyl-prolyl cis-trans isomerase B | VLEGMEVV | HLA-A2 | Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004 |
| lymphocyte-specific protein tyrosine kinase | KLVERLGAA | HLA-A2 | Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004 |
| Serine/threonine-protein kinase WNK2 | DLLSHAFFA | HLA-A2 | Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004 |
| Plasmanylethanolamine desaturase | RLQEWCSVI | HLA-A2 | Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004 |
| Dermatan-sulfate epimerase | DYSARWNEI | HLA-A*24:02 | Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004 |
| Prostatic acid phosphatase | LYCESVHNF | HLA-A*24:02 | Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J Immunother 2005 |
| Claudin-18 | YTFGAALFV | HLA-A*02:01 | Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022 |
| Claudin-18 | GLLVSIFAL | HLA-A*02:01 | Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022 |
| Claudin-18 | TLTSGIMFI | HLA-A*02:01 | Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022 |
| Claudin-18 | GLPAMLQAV | HLA-A*02:01 | Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022 |
| Claudin-18 | TLTSGIMFIV | HLA-A*02:01 | Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022 |
| Claudin-18 | STGFGSNTK | HLA-A*11:01 | Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022 |
| Claudin-18 | LLVSIFALK | HLA-A*11:01 | Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022 |
| Claudin-18 | VAYKPGGFK | HLA-A*11:01 | Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022 |
| Claudin-18 | SVAYKPGGFK | HLA-A*11:01 | Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022 |
| Claudin-18 | HASGHSVAYK | HLA-A*11:01 | Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022 |
| Claudin-18 | GLLVSIFALK | HLA-A*11:01 | Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022 |
重点说明：Claudin-18作为靶点的在研药物有70多种进入临床试验，该靶点是胃癌领域的热点研发领域。其中，CLDN18.2是研究最为透彻的CLDN18蛋白成员。
CLDN18.2通常存在于胃黏膜细胞的紧密连接处，维持胃粘膜的屏障功能，防止胃酸的H+通过细胞旁路途径渗透。CLDN18.2在正常组织中表达有限，而在多种恶性肿瘤发展中异常表达，如胃癌/胃食管交界处癌症（GC/GEJ）、乳腺癌、结肠癌、肝癌、头颈癌、支气管癌和非小细胞肺癌。CLDN18.2参与肿瘤细胞的增殖、分化和迁移。癌组织的紧密连接被破坏，导致CLDN18.2结合表位暴露出来。
这使靶向的大分子药，比如抗体药物，甚至CAR-T细胞治疗药物更易与肿瘤部位的CLDN18.2结合，而不与正常组织中的CLDN18.2结合，减小毒副作用。
胃瘤抗原清单使用方法：
肿瘤微环境研究：
检测肿瘤浸润淋巴细胞中，肿瘤抗原特异性淋巴细胞的数量实现。具体方式是：根据清单内容，将抗原肽和HLA合成为抗原肽MHC复合物荧光四聚体，通过流式细胞检测方法，检测肿瘤浸润淋巴细胞的含量。
肿瘤免疫细胞的全身分布：
通过检测外周血中肿瘤抗原特异性淋巴细胞的数量实现。具体方法同上。
过继性肿瘤免疫细胞治疗：
使用清单中抗原肽，刺激淋巴细胞，而后使用抗原肽MHC复合物荧光四聚体或磁珠四聚体，通过流式分选或磁珠分选细胞，经体外细胞增殖后，回输体内，评估肿瘤抑制效果。
肿瘤抗原特异性TCR测序：
通过肿瘤浸润淋巴细胞、或外周血淋巴细胞，通过分选后进行单细胞TCR测序，获得抗原特异性T细胞的TCR序列，进一步进行TCR-T疗法研究。
肿瘤疫苗片段筛选：
综合上述过程，获得具有激活T细胞杀伤肿瘤细胞的经验证抗原肽MHC复合物，用于肿瘤疫苗构建。
